1 min readAffymetrix Extends Collaborations in Cancer Research Program
Santa Clara, CA. – Affymetrix has announced that it has extended its Collaborations in Cancer Research Program (CCRP) to North America, forming an alliance between Affymetrix and 25 leading cancer researchers. According to the company, the expansion builds on the success of the European CCRP, launched in April 2007. All of the researchers in the program are using Affymetrix’ integrated genomics solution to accelerate research on more than 10 types of cancer.
The Affymetrix integrated genomics solution combines copy number data from the SNP Array 6.0 and expression information from the Human Exon 1.0 ST Array to deliver a comprehensive view of the cancer genome. This integrated genomics approach accelerates the discovery and validation of candidate genes associated with the disease.
CCRP participants were selected on the basis of past contributions to their respective fields and potential to make significant advancements in cancer research. The Affymetrix integrated solution provides researchers with a deeper understanding of the cancer genome by incorporating genome-wide expression, exon and alternative splice information, as well as genotype, copy number and loss of heterozygosity data from just two arrays.
“We are using the SNP 6.0 arrays to obtain the most comprehensive profile of genomic abnormalities aimed at discovering novel molecular targets,” said Dr Tak Mak Wah, professor at the Department of Medical Biophysics, University of Toronto. “The ability to integrate the exon and SNP array data will help us identify candidate driver genes underlying these genomic abnormalities and speed up their validation.”
“The genomics of cancer disparities among racial minorities is a rapidly evolving field,” said Dr Norman H. Lee, professor at the Department of Pharmacology and Physiology, George Washington University Medical Centre. “We are excited to be partnering with Affymetrix to identify and investigate new molecular targets as a prelude to reduce cancer health disparities.”
Initial data from the studies will be released in the next three to six months. Speakers from the program can be heard at the integrated genomics conference series hosted by Affymetrix, beginning in mid-May.
As part of the program, Affymetrix is partially funding selected research projects that demonstrate clinical utility, in addition to helping participants obtain tools and training, and providing forums where investigators can exchange knowledge and share best practices.